On January 29, 2019 Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, reported that Dr. Paul Lammers, President & CEO, will both present and moderate a round table discussion at the CAR-T Congress EU, to be held in London UK on January 30-31 (Press release, Triumvira Immunologics, JAN 29, 2019, https://triumvira.com/press-releases/triumvira-immunologics-to-present-at-car-t-congress-eu-in-london-uk/ [SID1234532937]). The invitations acknowledge Triumvira’s expertise in the novel engineering of T cells for the potential treatment of hematological malignancies and solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The CAR-T Congress EU is a forum focused on discovering, translating, developing, and commercializing CAR-T into viable and accessible therapies. CAR-T cell therapies have shown transformational activity in hematological malignancies. However, despite the tremendous success so far, there are still hurdles to overcome before CAR-T can be effective in mainstream oncology beyond hematological malignancies. The European CAR-T Congress’ mission is to address the opportunities and challenges that presently face the CAR-T field and maximize the potential of this ground-breaking therapy. As Triumvira’s proprietary T cell Antigen Coupler (TAC) technology is biologically distinct from CAR-T and has the potential to be a next-generation solution, Triumvira seeks to address some of the challenging areas for existing therapies in hematological malignancies and expand treatment activity to solid tumors.
Paul Lammers, MD, MSc, President, and Chief Executive Officer will present and lead a round table discussion at CAR-T Congress EU as follows:
Date: Wednesday, January 30, 2019
Time: 14:20 (GMT)
Venue: Millennium Gloucester Hotel, 4-18 Harrington Gardens, Kensington, London, SW7 4LH
Presentation: Triumvira’s TAC-T cell Technology: A Step Forward in Adoptive T Cell Therapy.
Date: Thursday, January 31, 2019
Time: 10:30 (GMT)
Venue: Millennium Gloucester Hotel, 4-18 Harrington Gardens, Kensington, London, SW7 4LH
Moderating Round Table: Critical Challenges Facing CAR-T Therapy: Strengthening CAR-T for Solid Tumors.